Adstiladrin
nadofaragene firadenovec · IFN-alpha2b (adenovirus, intravesical)Not conducted for rAd-IFN; conducted for excipient Syn3 only (Ames and chromosome aberration, negative)
Vyjuvek: genotox, carcinogenicity and repro: done or skipped?
beremagene geperpavec · COL7A1 (HSV-1, topical)
Genotoxicity
Not conducted (HSV-1 does not integrate; negligible insertional mutagenesis)
“No traditional genotoxicity studies were performed.”
Carcinogenicity
Not conducted; weight-of-evidence literature risk assessment
“No carcinogenicity studies were performed, and the applicant provided a weight of evidence risk assessment”
Instead of carcinogenicity
Weight-of-evidence risk assessment from a literature search up to July 2024; no association of HSV-1 infection with cancer
“No carcinogenicity studies were performed, and the applicant provided a weight of evidence risk assessment, based on a literature search up to July 2024. This did not identify any association or risk factor identification for HSV-1 infection and cancer.”
Instead of genotoxicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
DRG histopathology
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Reproductive & developmental
Not conducted (acceptable given product characteristics and safety profile)
“Animal reproductive and developmental toxicity (DART) studies were not conducted with VYJUVEK.”
Safety pharmacology
Not conducted (locally administered, limited distribution)
“No safety pharmacology studies with KB-103 were performed.”
Genotox: Ames
Not conducted (non-integrating HSV-1 vector; low insertional mutagenesis risk)
“No genotoxicity studies with VYJUVEK were performed because HSV-1 does not integrate into or disrupt the host genome; therefore, the risk of insertional mutagenesis of KB103 is low.”
Genotox: in vitro mammalian
Not conducted (non-integrating HSV-1 vector; low insertional mutagenesis risk)
“No genotoxicity studies with VYJUVEK were performed because HSV-1 does not integrate into or disrupt the host genome; therefore, the risk of insertional mutagenesis of KB103 is low.”
Genotox: in vivo
Not conducted (non-integrating HSV-1 vector; low insertional mutagenesis risk)
“No genotoxicity studies with VYJUVEK were performed because HSV-1 does not integrate into or disrupt the host genome; therefore, the risk of insertional mutagenesis of KB103 is low.”
Carcinogenicity model
Not conducted; weight-of-evidence literature risk assessment instead
“No carcinogenicity studies were performed, and the applicant provided a weight of evidence risk assessment, based on a literature search up to July 2024.”
Carcinogenicity timing
Not required (no carcinogenic risk indicated by data for KB103 and wild-type HSV-1)
“No carcinogenicity/tumorigenicity studies with VYJUVEK were performed because available data for both KB103 and wild-type HSV-1 do not indicate a carcinogenic risk in humans.”
hERG / QT
Not conducted (no safety pharmacology studies)
“No safety pharmacology studies with KB-103 were performed.”
Same question, other gene therapies
Beqvez
fidanacogene elaparvovec · Factor IXNot conducted (classical); vector integration site analysis in dog and NHP liver instead
Casgevy
exagamglogene autotemcel · BCL11A enhancer (CRISPR-Cas9, ex vivo HSC)No conventional studies; specialized on-/off-target editing (GUIDE-seq, in silico, hybrid capture) and chromosomal aberration assessments
Elevidys
delandistrogene moxeparvovec · Micro-dystrophinNot conducted (low-frequency random AAV integration per literature)
Fayuvi
rebisufligene etisparvovec · SGSH (AAV9)Not conducted; weight-of-evidence risk assessment used
Genglycos
pariglasgene brecaparvovec · G6PC (AAV8)Not conducted (low AAV integration risk); vector integration assessed in germline transmission study
Glybera
alipogene tiparvovec · LPL (AAV1)Not conducted (standard tests not relevant); integration studies (LAM-PCR, nrLAM-PCR) instead
Hemgenix
etranacogene dezaparvovec · Factor IXNot conducted as standard battery; integration site analysis (LAM-PCR) in mouse and NHP liver showed low random integration
Imlygic
talimogene laherparepvec · GM-CSF (oncolytic HSV-1)Not conducted (ICH S6(R1))
Itvisma
onasemnogene abeparvovec (intrathecal) · SMN1 (AAV9, intrathecal)Not conducted (single administration, known product characteristics, class safety profile)
Kebilidi
eladocagene exuparvovec · AADCNot conducted (agreed with CHMP; low integration risk in post-mitotic neurons)
Kresladi
marnetegragene autotemcel · ITGB2 (LVV, ex vivo HSC)Integration site analyses only (mouse and human transduced cells); no standard genotoxicity battery
Lenmeldy
atidarsagene autotemcel · ARSA (LVV, ex vivo HSC)Conducted: integration site analysis, in vitro immortalization assay, tumor-prone Cdkn2a-/- mouse; no insertional transformation
Luxturna
voretigene neparvovec · RPE65Not conducted (AAV low integration frequency; limited systemic exposure)
Lyfgenia
lovotibeglogene autotemcel · HBB T87Q (LVV, ex vivo HSC)Insertional mutagenesis assessed: in vitro immortalization (IVIM) assay and integration site analyses; low risk
Otarmeni
lunsotogene parvec · OTOF (AAV, intracochlear)Not conducted (low AAV insertional mutagenesis risk; limited distribution beyond inner ear)
Papzimeos
zopapogene imadenovec · HPV6/11 antigens (gorilla adenovirus)Not conducted (non-integrating, replication-incompetent adenovector; no insertional mutagenesis)
Roctavian
valoctocogene roxaparvovec · Factor VIIINot conducted (literature on AAV); NHP liver integration site analysis: 1.55x10^-3 IS/cell, no clonal expansion
Skysona
elivaldogene autotemcel · ABCD1 (LVV, ex vivo HSC)Standard genotox not relevant; insertional mutagenesis assessed by in vitro immortalization assay and integration site analysis
Strimvelis
autologous CD34+ cells transduced with ADA (no INN) · ADA (gamma-retroviral, ex vivo HSC)Not conducted (conventional assays cannot detect insertional events)
Tudriqev
vusolimogene oderparepvec · GALV-GP + GM-CSF (oncolytic HSV-1)Not conducted (not warranted based on product characteristics and safety profile)
Waskyra
etuvetidigene autotemcel · WAS (LVV, ex vivo HSC)Conventional mutagenicity not conducted; IVIM assay, vector insertion site analysis and VITA performed, no genotoxic potential
Zevaskyn
prademagene zamikeracel · COL7A1 (RV-modified keratinocyte sheets)Not conducted (integration site analysis in transduced RDEB keratinocytes instead; no clonality or oncogene preference)
Zolgensma
onasemnogene abeparvovec · SMN1Not conducted (low random rAAV integration per literature)
Zynteglo
betibeglogene autotemcel · HBB T87Q (LVV, ex vivo HSC)Insertional mutagenesis assessed instead of standard genotox: in vitro immortalization assay (low potential) and integration site analysis (no clonal dominance)